Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease
Year: 2020
Type: article
Abstract: RATIONALE: chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and common in older adults. The BODE Index is the most recognised mortality risk score in COPD but includes a 6-minute walk test (6MWT) that is seldom available in practise; the BODE Index may be better adopted if the 6MWT was replaced. OBJECTIVES: we investigated whether a modified BODE Index in which 6MWT was replaced by an alternative measure of physical capacity, specifically the short physical performance battery (SPPB) or components, retained its predictive ability for mortality in individuals with COPD. METHODS: we analysed 630 COPD patients from the ERICA cohort study for whom UK Office for National Statistics verified mortality data were available. Variables tested at baseline included spirometry, 6MWT, SPPB and its components (4-m gait speed test [4MGS], chair stand and balance). Predictive models were developed using stratified multivariable Cox regression, and assessed by C-indices and calibration plots with 10-fold cross-validation and replication. RESULTS: during median 2 years of follow-up, 60 (10%) individuals died. There was no significant difference between the discriminative ability of BODE6MWT (C-index 0.709, 95% confidence interval [CI], 0.680-0.737), BODESPPB (C-index 0.683, 95% CI, 0.647-0.712), BODE4MGS (C-index 0.676, 95% CI, 0.643-0.700) and BODEBALANCE (C-index 0.686, 95% CI, 0.651-0.713) for predicting mortality. CONCLUSIONS: the SPPB, and its 4MGS and balance components, can potentially be used as an alternative to the 6MWT in the BODE Index without significant loss of predictive ability in all-cause mortality.
Source: Age and Ageing
Institutions: University of Cambridge, GlaxoSmithKline (United States), University of Nottingham, Nottingham Biomedical Research Centre, Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Columbia University Irving Medical Center, Columbia University, Cambridge University Hospitals NHS Foundation Trust, GlaxoSmithKline (United Kingdom), National Institute for Health and Care Research, The Alan Turing Institute, MRC Biostatistics Unit, Health Data Research UK, NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Clinical Trials Unit, Royal Brompton Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,699
Funders: Wellcome Trust, National Institute for Health and Care Research, British Heart Foundation, Department of Health and Social Care, Public Health Agency, Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Health and Social Care Research and Development Division, Health Data Research UK
Awards: Large-scale integrative genomic studies of high-dimensional traits in cardiovascular diseases (renewal), G4211044638, NIHR Senior Investigator Award, Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application (renewal). (Joint funding with MRC), Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application
OpenAlex ID: W3083992826
